Alumis Inc. (NASDAQ:ALMS – Get Free Report) insider Roy Hardiman sold 2,692 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $70,988.04. Following the sale, the insider owned 207,746 shares of the company’s stock, valued at $5,478,262.02. This trade represents a 1.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.
Alumis Trading Up 2.5%
ALMS opened at $27.80 on Friday. Alumis Inc. has a 1-year low of $3.76 and a 1-year high of $31.35. The company has a market cap of $3.54 billion, a price-to-earnings ratio of -14.04 and a beta of -0.69. The company’s fifty day moving average price is $25.50 and its two-hundred day moving average price is $25.25.
Alumis (NASDAQ:ALMS – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). The business had revenue of $1.74 million for the quarter, compared to analyst estimates of $2.10 million. Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. As a group, equities analysts forecast that Alumis Inc. will post -2.87 earnings per share for the current fiscal year.
Alumis News Summary
- Positive Sentiment: Institutional ownership has generally increased, including a significant expansion of Geode Capital Management’s position and additional buying by Goldman Sachs, Rhumbline Advisers and other investors. Such activity may provide some support for Alumis shares, although the reported purchases occurred in prior quarters.
- Neutral Sentiment: HC Wainwright reaffirmed a “Neutral” rating on ALMS and maintained a $25 price target, suggesting the firm does not currently see a catalyst strong enough to support a more bullish outlook. HC Wainwright Reaffirms Neutral Rating for Alumis
- Negative Sentiment: Six insiders collectively sold 14,953 shares of Alumis at an average price of $26.37, generating approximately $394,311. Sellers included CFO John R. Schroer, whose position fell 11.72%, along with Mark Christopher Bradley, Jorn Drappa, David M. Goldstein, Roy C. Hardiman and Sanam Pangali. The transactions reduced individual holdings by roughly 1.28% to 12.28% and could weigh on investor sentiment because of the concentration of sales. However, insider sales can also reflect personal financial planning rather than a change in the company’s outlook. Alumis Insider Sale Filings
- Negative Sentiment: Alumis remains a clinical-stage biotechnology company with substantial losses. Its latest quarterly results missed both earnings and revenue expectations, while analysts forecast a full-year loss of approximately $2.87 per share. This limits fundamental support until the company reports meaningful clinical or development progress.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALMS. MPM Bioimpact LLC purchased a new position in shares of Alumis in the 4th quarter worth approximately $23,443,000. Janus Henderson Group PLC purchased a new stake in shares of Alumis during the first quarter valued at approximately $46,790,000. Orbimed Advisors LLC purchased a new stake in shares of Alumis during the second quarter valued at approximately $5,779,000. Woodline Partners LP lifted its holdings in Alumis by 809.7% during the third quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock worth $6,987,000 after acquiring an additional 1,558,660 shares during the period. Finally, Samsara Biocapital LLC lifted its holdings in Alumis by 47.0% during the second quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock worth $14,404,000 after acquiring an additional 1,534,872 shares during the period.
Wall Street Analyst Weigh In
A number of analysts have commented on ALMS shares. HC Wainwright reissued a “neutral” rating and set a $25.00 price objective on shares of Alumis in a report on Monday. Morgan Stanley restated an “overweight” rating and issued a $39.00 target price on shares of Alumis in a report on Friday, May 15th. Wells Fargo & Company lifted their target price on Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a research report on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alumis in a report on Tuesday, July 7th. Finally, Citigroup reissued a “buy” rating on shares of Alumis in a research report on Tuesday, May 19th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $40.30.
Get Our Latest Research Report on Alumis
About Alumis
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Read More
- Five stocks we like better than Alumis
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.
